Unweighted average TNFi survival rates according to concomitant DMARD use (all treatment lines included).
| Treatment Regimens | 12 Months Followup, % Survival | 24 Months Followup, % Survival | 48 Months Followup, % Survival |
|---|---|---|---|
| TNFi monotherapy | |||
| ADA | 59 (n = 2631) | 48 (n = 2751) | 44 (n = 2661) |
| ETN | 72 (n = 4662) | 55 (n = 4886) | 46 (n = 4637) |
| IFX | 56 (n = 3211) | 37 (n = 3272) | 30 (n = 3127) |
| Combination therapy | |||
| ADA + concomitant DMARD | 68 (n = 1389) | 59 (n = 903) | 42 (n = 525) |
| ETN + concomitant DMARD | 73 (n = 6105) | 66 (n = 1806) | 51 (n = 1129) |
| GOL + concomitant DMARD | 88 (n = 139) | Not reported | Not reported |
| IFX + concomitant DMARD | 76 (n = 4468) | 56 (n = 3551) | 38 (n = 2854) |
DMARD: disease-modifying antirheumatic drug; TNFi: tumor necrosis factor inhibitor; ADA: adalimumab; ETN: etanercept; IFX: infliximab; GOL: golimumab.